Experimental Immunotherapy Shows Strong Results in High-Risk Bladder Cancer Trial

An international Phase III study published in The Lancet Oncology reported positive findings for cretostimogene grenadenorepvec, an experimental immunotherapy for BCG-unresponsive, non-muscle-invasive bladder cancer. The treatment demonstrated 75% complete responses, with 60% of patients remaining cancer-free for two years, offering a potential bladder-sparing alternative to surgical removal.